Chi Van Dang
From Wikipedia, the free encyclopedia
Chi Van Dang is a hematological oncologist and researcher, currently serving as the Scientific Director of Ludwig Institute for Cancer Research.[1] He is known for his research on genetics, the MYC gene and the cellular energy metabolism of cancer.
Dang has served as president of the American Society for Clinical Investigation.[2] He has been elected to the National Academy of Medicine,[2] the American Association for Cancer Research,[3] the American Academy of Arts and Sciences,[4] the American Society for Clinical Investigation,[2] and the Association of American Physicians,[5] among others.
Chi Van Dang was born in Saigon, Vietnam[6] as one of ten children.[7] Dang's father was Chieu Van Dang, Vietnam's first neurosurgeon and was once the dean of the University of Saigon School of Medicine.[1][7]
After arriving in the United States in 1967, Dang completed his B.S. degree in Chemistry at the University of Michigan in 1975,[2] his Ph.D in chemistry at Georgetown University in 1978, and M.D. from Johns Hopkins University, in 1982.[7][8] At the University of California, San Francisco, he completed a fellowship on Hematology-Oncology training where he began to work with the MYC gene.[9]
Career
In 1987, Dang returned to Johns Hopkins where he took a faculty position. He was Director of the Division of Hematology at Johns Hopkins Hospital from 1993-2003.[10] He also served as Johns Hopkins Family Professor in Oncology Research. As of 2002, he became Vice Dean for Research,[11] and Director of the Johns Hopkins Institute for Cell Engineering.[12][7]
From 2002 to 2003, Dang was the President of the American Society for Clinical Investigation.[2] In his 2003 presidential address, he remarked, "I wish to remind all of us of the power of healing. Be it in the laboratory, at the cageside, bedside or computerside, we, as physicians, all have the ability to heal."[13]
As of September 1, 2011, Dang became the John H. Glick Professor of Medicine[14] and the Director of the Abramson Cancer Center at the University of Pennsylvania.[11]
As of July 1, 2017, Dang became the Scientific Director of the Ludwig Institute for Cancer Research, with the responsibility of overseeing the Institute's scientific strategy for studying the prevention, diagnosis, and treatment of cancer.[12] The Ludwig Institute has branches in the United States, Switzerland, and the United Kingdom.[7] He was also appointed a professor at the Wistar Institute on the campus of the University of Pennsylvania, which hosts the Ludwig Laboratory during his tenure as The Ludwig Institute's Scientific Director.[15][16]
In 2018, Dang became Editor-in-Chief of Cancer Research, a peer-reviewed scientific journal published by the American Association for Cancer Research. He published his first editorial in January.[17][18]